The KCI ART is expected to investigate emerging medical therapies and technologies to fuel product development and commercialisation.
The ART will focus on conducting applied research to develop new clinical applications that leverage KCI’s existing portfolio of proprietary technologies.
Additionally, ART Center will develop collaborative relationships with universities around the world to identify future technologies of relevance to KCI’s mission
Specific priorities include developing more mobile and compact wound healing technologies for home care settings, and identifying new clinical applications for KCI’s regenerative medicine business beyond the repair of soft-tissue defects.
Further, Kinetic Concepts has appointed David McQuillan as a senior vice president of ART.
Cathy Burzik, president and CEO of KCI, said: “The history of human achievement shows us that the greatest innovations occur in an environment that promotes collaboration, creativity and intellectual curiosity. That is KCI’s culture, and that is our vision for this center.”